GW Pharmaceuticals PLC- (GWPH) Lifted to Hold at Zacks Investment Research

GW Pharmaceuticals PLC- (NASDAQ:GWPH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

A number of other analysts have also recently weighed in on GWPH. Cantor Fitzgerald set a $208.00 target price on shares of GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a report on Monday, December 4th. Goldman Sachs upgraded shares of GW Pharmaceuticals PLC- from a “neutral” rating to a “buy” rating and set a $174.00 target price for the company in a report on Thursday, December 14th. BidaskClub upgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. Leerink Swann restated a “buy” rating and set a $153.00 target price on shares of GW Pharmaceuticals PLC- in a report on Tuesday, January 23rd. Finally, Bank of America reduced their target price on shares of GW Pharmaceuticals PLC- from $154.00 to $149.00 and set a “buy” rating for the company in a report on Tuesday, February 6th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the stock. GW Pharmaceuticals PLC- has a consensus rating of “Buy” and an average price target of $146.38.

GWPH stock opened at $117.31 on Wednesday. GW Pharmaceuticals PLC- has a 12 month low of $92.65 and a 12 month high of $143.37. The company has a current ratio of 11.44, a quick ratio of 11.34 and a debt-to-equity ratio of 0.01. The company has a market cap of $3,299.63, a P/E ratio of -14.00 and a beta of 2.63.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported ($2.43) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.03) by ($0.40). GW Pharmaceuticals PLC- had a negative net margin of 1,357.98% and a negative return on equity of 46.94%. The company had revenue of $7.73 million for the quarter, compared to analyst estimates of $2.18 million. research analysts expect that GW Pharmaceuticals PLC- will post -8.95 EPS for the current fiscal year.

A number of large investors have recently modified their holdings of the stock. Eqis Capital Management Inc. boosted its holdings in GW Pharmaceuticals PLC- by 12.6% during the fourth quarter. Eqis Capital Management Inc. now owns 3,791 shares of the biopharmaceutical company’s stock worth $500,000 after buying an additional 424 shares in the last quarter. Aperio Group LLC boosted its holdings in GW Pharmaceuticals PLC- by 12.0% during the fourth quarter. Aperio Group LLC now owns 5,325 shares of the biopharmaceutical company’s stock worth $703,000 after buying an additional 569 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in GW Pharmaceuticals PLC- by 18.6% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 3,700 shares of the biopharmaceutical company’s stock worth $376,000 after purchasing an additional 581 shares during the period. Bank of Montreal Can boosted its stake in GW Pharmaceuticals PLC- by 37.1% in the 4th quarter. Bank of Montreal Can now owns 2,625 shares of the biopharmaceutical company’s stock worth $347,000 after purchasing an additional 710 shares during the period. Finally, Raymond James & Associates boosted its stake in GW Pharmaceuticals PLC- by 9.3% in the 4th quarter. Raymond James & Associates now owns 8,464 shares of the biopharmaceutical company’s stock worth $1,117,000 after purchasing an additional 718 shares during the period. Hedge funds and other institutional investors own 82.51% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “GW Pharmaceuticals PLC- (GWPH) Lifted to Hold at Zacks Investment Research” was first posted by Stock Observer and is the property of of Stock Observer. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.thestockobserver.com/2018/03/21/gw-pharmaceuticals-plc-gwph-lifted-to-hold-at-zacks-investment-research.html.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply